In its 2023 Investor Day Presentation yesterday, Boston Scientific forecast organic sales CAGR of 8%-d10%, “above historical growth bolstered by key market launches” as well as 150bps of adjusted operating margin expansion, strong double digit adjusted EPS, growth and enhanced free cash flow conversion for the 2024-2026 period.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BSX:
- CVS Health appoints Boston Scientific CEO Michael Mahoney to board
- Boston Scientific price target raised to $63 from $60 at Baird
- Boston Scientific price target raised to $60 from $56 at Mizuho
- Boston Scientific Announces Agreement to Acquire Relievant Medsystems, Inc.
- Boston Scientific signs agreement to acquire Relievant Medsystems